Whitehawk Therapeutics, Inc. (WHWK): Cost of Revenue
$760.0K
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
-17.1%
3-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $760.0K | -74.9% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $3.02M | +7.7% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $2.81M | +110.4% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $1.33M | n/a | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $0 | n/a | 2023-03-29, From 2021-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $760.0K | -74.9% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $2.09M | -25.1% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.03M | +7.1% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $3.77M | +93.0% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $2.96M | -57.2% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $4.28M | -34.4% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $857.0K | -28.6% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $6.64M | -14.5% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $7.04M | -17.6% |
Compare WHWK, ACRS, ISCO, JAGX side by side · Screen every company in Pharmaceutical Preparations ↗